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ABSTRACT 
Background International guidelines recommend that an average individual time in 
therapeutic range should be >65-70% for optimal efficacy and safety outcomes whilst 
on a vitamin K antagonists (VKA). The SAMe-TT2R2 score would help decision making 
by identifying those newly diagnosed atrial fibrillation patients that could do well on 
vitamin K antagonists.  
Objective  To validate the predictive value of the SAMe-TT2R2 score for 
discriminating those who would achieve a high time in therapeutic range(≥65%) in a 
prospective ‘real world’ cohort of atrial fibrillation patients initiating oral 
anticoagulation therapy with VKA. 
Methods    We studied an inception cohort of consecutive non-valvular atrial 
fibrillation patients that initiated oral anticoagulation in our outpatient anticoagulation 
clinic. Baseline SAMe-TT2R2 score was calculated.  At 6 months, we calculated time in 
therapeutic range using the Rosendaal method.  
Results  We included 459 patients: 222 (47%) male, median age 76 (interquartile 
range70-82); Median CHA2DS2-VASc score was 4 (3-5) and medianHAS-BLED score was 
3 (2-3). Median SAME-TT2R2 score was 2 (1-2).  
At 6 months, the mean ± standard deviationtime in therapeutic range at was 64±17% 
overall, and 248 (54%) patients had a time in therapeutic range value >65%. Patients 
with a SAME-TT2R2 score 0-1 had a mean time in therapeutic range of 67±18% whereas 
in patients with a SAME-TT2R2score ≥2, mean time in therapeutic range was 61±16%, 
p<0.001. The odds ratio (OR) for having a low time in therapeutic range value was 2.10 
(95%CI 1.44-3.06, p<0.001) for those patients with a SAME-TT2R2 score ≥2.  
Conclusions   In a prospective ‘real world’ inception cohort of atrial fibrillation patients 
initiating oral anticoagulation with acenocoumarol, we have validated the clinical value 
of the SAME-TT2R2 score, for the identification of patients who would have poor quality 
anticoagulation. Thus, rather than imposing a ‘trial of vitamin K antagonists’ for such 
patients (and exposing such patients to thromboembolic risks), we can a priori identify 
those patients who can (not cannot) do well on a vitamin K antagonists. Such patients 
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would benefit from additional strategies for improving anticoagulation control with 
VKAor alternative oral anticoagulant drugs.  
 
Key words:  time in therapeutic range, acenocoumarol, atrial fibrillation, 
anticoagulation 
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INTRODUCTION 
Atrial fibrillation is associated with high morbidity and mortality, with an increased risk 
of stroke and thromboembolism
1
. Oral anticoagulation is highly effective reducing the 
risk of stroke and mortality, compared to placebo/control 
2
. However, the efficacy and 
safety of VKA depends upon the quality of anticoagulant control, as reflected by the 
average percentage of the time in therapeutic range of INR 2.0-3.0.  Various studies 
have shown how a high time in therapeutic range translates into a lower risk of stroke 
and bleeding, whilst on oral anticoagulation
3-5
.  A recent European consensus 
document recommends that an average individual time in therapeutic range should be 
>70% for optimal efficacy and safety outcomes whilst on a vkaS
6,7
 and this is also 
recommended in the European Guidelines for the management of AF
8
.  In the National 
Institute for Health and Care Excellence (NICE) guidelines, a time in therapeutic range 
of >65% is recommended for patients with atrial fibrillation who are taking VKA 
therapy 
9
. 
In 2013, Apostolakis et al. 
10
proposed and validated the SAMe-TT2R2 score [Sex, Age 
(<60 years), Medical history (at least 2 of the following: hypertension, diabetes, 
coronary artery disease/myocardial infarction, peripheral arterial disease, congestive 
heart failure, previous stroke, pulmonary disease, hepatic or renal disease), Treatment 
(interacting drugs eg. amiodarone for rhythm control) [all 1 point], as well as current 
Tobacco use (2 points) and Race (non-Caucasian; 2 points)]. This simple clinical score 
(SAMe-TT2R2) could help decision making by identifying those atrial fibrillation patients 
that would probably do well on VKAs with a high average time in therapeutic range (ie. 
those with SAMe-TT2R2 score<2). 
We have recently validated this score in a retrospective analysis of our “real world” 
anticoagulated atrial fibrillation patients
11
. Also, a high SAMe-TT2R2 score (reflecting 
poor anticoagulation control with poor time in therapeutic range) was associated with 
more bleeding, adverse cardiovascular events and mortality during follow-up. Prior 
validation studies 
11-13
 have been made on retrospective analysis of clinic or hospital 
cohort studies, and thus, the objective of the present study was to validate a priori the 
use of the SAMe-TT2R2 score in a contemporary inception cohort of anticoagulation-
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naïve atrial fibrillation patients who were prospectively initiating oral anticoagulation 
with a vitamin K antagonist, acenocoumarol.  
 
 
METHODS 
We included consecutive non-valvular atrial fibrillation patients that initiating oral 
anticoagulation with acenocoumarolin our out-patient anticoagulation clinic, between 
January and December 2013, who maintained oral anticoagulation and were followed 
up prospectively for 6 months, for this study. This inception cohort of patients was 
anticoagulation-naïve at baseline. 
A complete medical history was recorded at inclusion. Baseline stroke risk was 
assessed using the CHA2DS2-VASc [Cardiac failure or dysfunction, Hypertension, Age 
over 75 years [Doubled], Diabetes, Stroke [Doubled] – Vascular disease, Age between 
65-74 and Sex category [Female]) score, as described in recent guidelines
8,14
. The HAS-
BLED bleeding risk score was calculated as a measure of baseline bleeding risk, as the 
result of adding one point to hypertension, abnormal renal/liver function (one point 
each), stroke, bleeding history or predisposition, labile INR, elderly (age over 65) and 
drugs/alcohol concomitantly (one point for each one)
15
.  
At baseline SAMe-TT2R2 score was calculated as previously described 
10
. At six months 
we calculated time in therapeutic range using the established Rosendaal method
16
. 
Once the patient reached steady dose, the frequency of INR testing was once a month, 
so all patients had a minimum of 8 visits. 
Exclusion criteria 
Patients with valvular atrial fibrillation (prosthetic or not) were excluded. We also 
excluded those patients that did not receive at least 6 months oral anticoagulation 
treatment, those suffered from any event leading to temporarily discontinue oral 
anticoagulation, as this would influence achievement of stable anticoagulation.  
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Statistical analysis 
Continuous variables were tested for normality by the Kolmogorov-Smirnov test. 
Continuous variables are presented as a mean ± SD or median (interquartile range), as 
appropriate, and categorical variables as a percentage. Differences were compared 
using the student t-test or Mann-Whitney test, as appropriate.  The association 
between SAMe-TT2T2 score and low time in therapeutic range (<65%) was assessed by 
logistic regression model. A P <0.05 was accepted as statistically significant. Statistical 
analyses were performed using SPSS 15.0 for Windows (SPSS, Inc., Chicago, Ill). 
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RESULTS 
 
During January to December 2013, 719 consecutive patients with non-valvular atrial 
fibrillation were initiated on oral anticoagulation with acenocoumarol in our out-
patient anticoagulation clinic. This anticoagulation clinic serves a population of 
500,000 and approximately 7,500 patients are treated annually (of these, 62% are 
patients with atrial fibrillation).  Based on our study inclusion/exclusion criteria, only 
459 patients (64% of the whole cohort) entered the final analysis [Table 1].  The 
reasons for exclusion patients were as follows: 74 patients (28%) needed interruption 
for surgical intervention or any other invasive procedure; in 73 (28%) patients their 
primary care doctor stopped oral anticoagulation for several reasons (advanced age, 
patient preference); 51 (20%) patients stopped oral anticoagulation one month after 
effective cardioversion; 44 patients were moved to another anticoagulation clinic 
(17%); and 18 (7%) patients changed to a Non-vitamin K antagonists antagonist Oral 
Anticoagulant (NOAC, previously referred to as new or novel oral anticoagulant) before 
reaching 6 months of anticoagulation treatment with VKAs (see flowchart, figure 1) 
Our 459 patients included 222 (47%) males, with median age 76 (interquartile range, 
IQR 70-82), median CHA2DS2-VASc score of 4 [IQR 3-5; whereby 92% with CHA2DS2-
VASc score≥2] and median HAS-BLED score of 3 (IQR 2-3); 54% with HAS-BLED score 
≥3. 
Median SAMe-TT2R2 score was 2 (IQR 1-2) and 55% patients had a score <2. Only 18 
patients had a score >3. Overall the mean time in therapeutic range at six months was 
64±17%, and 248 patients (54%) had a time in therapeutic range value >65%.  
After a follow-up of 6 months, patients with a SAMe-TT2R2 score <2 had a mean time in 
therapeutic range value of 67±18% compared to a mean time in therapeutic range of 
61±16% amongst patients SAMe-TT2R2 score ≥2 [p=0.001]. The odds ratio (OR) for 
having a low time in therapeutic range for patients with a SAMe-TT2R2 score ≥2 was 
2.10 (95%CI 1.44-3.06, p<0.001).  
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There was no relationship between time in therapeutic range values at 6 months and 
thrombotic risk based on a CHA2DS2-VASc categorisation of <2 and ≥2, with mean TTRs 
of 64±17% vs 67±17%, respectively (p=0.232). For the HAS-BLED score, patients with a 
score <3 had a mean time in therapeutic range of 66±17% vs patients with HAS-BLED 
≥3, who had a mean time in therapeutic range value of 63±17% (p=0.08). 
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DISCUSSION 
In this study, we validated for the first time the value of SAMe-TT2R2 score in a large 
consecutive “real world” inception cohort of patients who were initiating oral 
anticoagulation. As our patients were on acenocoumarol, or paper gives an additional 
use of the SAMe-TT2R2score for this VKA drug, which is the second most commonly 
used coumarin (after warfarin) in the world.Based on our analysis, patients with a high 
SAMe-TT2R2 score (≥2) would have a 2 fold increased risk for suboptimal quality of oral 
anticoagulation, as assessed by a low time in therapeutic range value at 6 months after 
initiating treatment with a vitamin K antagonist.  
Despite the NOACs
17
 being increasingly used, the VKAsremain the main oral 
anticoagulation used in many countries, especially where economic considerations are 
a factor.  One criterion often used to sanction NOAC use is a time in therapeutic range 
value at 6 months <65% 
9,17
. Thus, many patients have to undergo a ‘trial of vitamin K 
antagonist’ (or ‘warfarin stress test’) to show that high time in therapeutic range 
cannot be achieved, before a NOAC is allowed. 
Thus, use of a simple score based on clinical risk factors allows the clinician to make an 
informed decision whether a non-anticoagulated atrial fibrillation patient is likely (or 
not) to do well on a vitamin K antagonist. This is relevant since average time in 
therapeutic range may be poor or suboptimal in inception cohorts for as long as 6 
months (being an average of 47% in one recent US study)
18
, and this may translate into 
worse thromboembolic outcomes in this inception phase, being increased by 70%
19
.  
Those patients with a high SAMe-TT2R2 can be justifiably started on a NOAC up front 
(without a ‘warfarin stress test’) or be targeted for additional interventions (eg. more 
intense education, regular review and follow-up, etc
20
) whilst those patients with a 
SAMe-TT2R2 score <2 can be started on a vitamin K antagonist, as they are likely to do 
well.  Such an approach is illustrated in Figure 2. 
The efficacy and safety of therapy is closely associated to the quality of oral 
anticoagulation management
6,11
. These patients are best managed in specialized 
anticoagulation clinics, which achieves higher values of time in therapeutic range and 
provides the best outcomes
6,18-22
. Even in clinical trials, patients in centres with high 
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average time in therapeutic range may have less profound differences in efficacy 
outcomes between NOACs and warfarin
23
. The maintenance dose of VKA is influenced 
by many different factors, including race, dietary vitamin K intake, comorbidities (eg. 
liver disease and acute illness) or whether the patient may be taking interacting 
drugs
24
. The average individual time in therapeutic range generally increases over 
time, but even in very well and experienced patients, their time in therapeutic range 
value can decrease during follow-up
11
. This is especially important in patients who 
initiate conventional oral anticoagulation more INR fluctuations occur during the first 3 
months
24
.  In our cohort, for example, we found that the average time in therapeutic 
range value at 6 months was 64% and only 49% had a time in therapeutic range value 
up to 65%.  
It is important to note that our study was performed using acenocoumarol as vitamin K 
antagonist drug. Compared to warfarin, acenocoumarol has a shorter half life, about 8 
hours
25
. Hence, patients taking acenocoumarol may be more likely to have unstable 
anticoagulation control than those taking warfarin
26
. In addition, acenocoumarol has 
been related with a higher risk for bleeding than warfarin
22
. Thus, use of the SAMe-
TT2R2 score in this population taking acenocoumarol as their drug may confer 
additional advantages. 
Prediction algorithms (including clinical and genetic data) for VKA treatment could also 
be another option
27
. However the use of these algorithms in clinical practice remains 
uncertain, given the contradictory results of two controlled trials of genotype-guided 
dosing
28-30
. In contrast to complex (and expensive) genotyping, we have now 
prospectively validated the use of an easy, simple and cheap score that would detect 
which atrial fibrillation patients are likely to do well on vitamin K antagonists(with 
good average time in therapeutic range).This is important since even small differences 
in time in therapeutic range could translate to lower risk of adverse events whilst on 
VKA
5
. 
Limitations 
We only included in those patients that continued treatment during the initial 6 
months, so some very high risk patients that suffer from acute events during the first 
months may have been excluded.  Given our small sample size and followup duration, 
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we would have been underpowered to examine thromboembolic and bleeding events 
in this cohort.  Also, the proportion of patients with a very high SAMe-TT2R2score (>3) 
was low. All patients included were Caucasian, who were managed in a dedicated 
anticoagulation clinic, where the average overall time in therapeutic range was 
reasonably good, at 64% time in therapeutic range. 
We made reference to NICE guidelines criteria for defining good time in therapeutic 
range (≥65%) as this was based following a comprehensive evidence synthesis and 
appraisal, as well as cost effectiveness
9
. They also considered poor anticoagulation 
control as defined by 2 INR values higher than 5 or 1 INR value higher than 8 within the 
past 6 months, 2 INR values less than 1.5 within the past 6 months or time in 
therapeutic range less than 65%; however, we did not perform these additional 
measures within our cohort. 
Finally, another limitation is the possibility that low time in therapeutic range could be 
due to low adherence to treatment, which would also affect the further treatment 
with NOACs if they would be used. However, patients regularly attended the 
anticoagulation clinic and were reviewed by nurses if INR was out of range.  
 
Conclusion 
In a prospective ‘real world’ inception cohort of anticoagulation-naïve patients 
initiating oral anticoagulation with acenocoumarol, we have validated the clinical value 
of the SAMe-TT2R2score, for the identification of which patients would have poor 
quality anticoagulation. These patients would benefit from additional strategies for 
improving anticoagulation control with VKA or alternative oral anticoagulant drugs.  
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Table 1. Baseline clinical characteristics 
 
Baseline characteristics N= 459 
Male sex, n(%) 222 (47%) 
Age, median (IQR)  
Age < 60 
76 (70-82) 
38 (8%) 
Hypertension  368 (80%) 
Diabetes mellitus  141 (31%) 
Heart failure 87 (19%) 
History of stroke or TIA 67 (15%) 
Peripherical embolism 23 (5%) 
Hepatic impairment  12 (3%) 
Renal impairment 51 (11%) 
Coronary artery disease 70 (15%) 
Hypercholesterolemia 186 (41%) 
Chronic obstructive pulmonary disease 50 (11%) 
Current smoking habit 38 (8%) 
Previous bleeding episode 37 (8%) 
Concomitant treatment 
Amiodarone 
Calcium antagonist 
Beta-blockers 
Digoxin 
 
72 (16%) 
44 (10%) 
273 (59%) 
33 (7%) 
CHA2DS2-VASc score,  median (IQR) 4 (3-5) 
HAS-BLED score, median (IQR) 3 (2-3) 
SAME-TT2R2 score, median (IQR) 2 (1-2) 
 
 
CHA2DS2-VASc: Cardiac failure or dysfunction, Hypertension, Age ≥75y [Doubled], 
Diabetes, Stroke [Doubled] – Vascular disease, Age 65-74y and Sex category 
[Female] 
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HAS-BLED: Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History 
or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly 
SAMe-TT2R2: Sex, Age (<60 years), Medical history (at least 2 of the following: 
hypertension, diabetes, coronary artery disease/myocardial infarction, peripheral 
arterial disease, congestive heart failure, previous stroke, pulmonary disease, hepatic 
or renal disease), Treatment (interacting drugs e.g. amiodarone for rhythm control) [all 
1 point], as well as current Tobacco use (2 points) and Race (non-Caucasian; 2 points)
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Figure 1 
 Flowchart of patient selection 
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Figure 2 
Incorporation of the SAME-TT2R2 score into clinical decision making for 
anticoagulation therapy in newly diagnosed anticoagulation-naïve patients with 
atrial fibrillation 
 
 
 
 
NOAC: non-vitamin K antagonist oral anticoagulant 
TTR: time in therapeutic range 
VKA: vitamin K antagonist 
*When calculating TTR, use a validated method (eg. Rosendaal method for computer-
assisted dosing) or proportion of test in range for manual dosing 
** Reasses for poor anticoagulation control 
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CLINICAL SIGNIFICANCE 
• In a prospective ‘real world’ inception cohort of AF patients initiating oral 
anticoagulation with acenocoumarol, we have validated the clinical value of 
the SAME-TT2R2 score, for the identification of patients who would have poor 
quality anticoagulation.  
• We can identify those patients who can (not cannot) do well on a VKA. Such 
patients would benefit from additional strategies for improving 
anticoagulation control with VKA or alternative oral anticoagulant drugs.  
 
